{'fraction_non_alphanumeric': 0.024203821656050957, 'fraction_numerical': 0.0, 'mean_word_length': 5.442622950819672, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Article Commentary: Drug–Drug Interactions in HIV Therapy: Is it All Clear?

Drug–drug interactions in HIV therapy have been known to the clinic from earliest days of HIV treatment. Hundreds of well-designed pharmacokinetic studies have been performed in either HIV-infected patients or, mostly, in healthy volunteers. Case reports generally are graded lower in terms of evidence-based medicine but sometimes provide valuable information. In this issue of Antiviral Therapy a case of virological failure on an atazanavir-containing regimen was explained by an interaction with charcoal that was used as self-medication for diarrhoea. Clinicians are invited to continue submitting well-documented case reports to increase knowledge on drug–drug interactions in HIV therapy even further.